TRIAP1 and osteosarcoma: Study of Li D. and colleagues demonstrated that circPVT1 sustains doxorubicin resistance in osteosarcoma by acting as a sponge for miRNA-137 leading to the upregulation of its target gene TP53-regulated inhibitor of apoptosis 1 (TRIAP1) suggesting that circPVT1 could be used as a promising therapeutic target of osteosarcoma treatment [58].